Search

Your search keyword '"Biliotti, Elisa"' showing total 6 results
Start Over Author "Biliotti, Elisa" Publisher wiley
6 results on '"Biliotti, Elisa"'

1. Evolution of SARS‐CoV‐2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID‐19 in an Italian reference hospital: Impact on clinical outcomes

Author

Mondi, Annalisa, primary, Mastrorosa, Ilaria, additional, Piselli, Pierluca, additional, Cimaglia, Claudia, additional, Matusali, Giulia, additional, Carletti, Fabrizio, additional, Giannico, Giuseppina, additional, Milozzi, Eugenia, additional, Biliotti, Elisa, additional, Di Bari, Silvia, additional, Chinello, Pierangelo, additional, Beccacece, Alessia, additional, Faraglia, Francesca, additional, Vittozzi, Pietro, additional, Mosti, Silvia, additional, Tetaj, Nardi, additional, Stazi, Giulia Valeria, additional, Pinnetti, Carmela, additional, Camici, Marta, additional, D'Annunzio, Alberto, additional, Marani, Alessandra, additional, Fabeni, Lavinia, additional, Specchiarello, Eliana, additional, Gruber, Cesare Ernesto Maria, additional, Villanacci, Alberta, additional, Minicucci, Sabrina, additional, Garbuglia, Anna Rosa, additional, Ianniello, Stefania, additional, Marchioni, Luisa, additional, Taglietti, Fabrizio, additional, D'Offizi, Gianpiero, additional, Palmieri, Fabrizio, additional, Nicastri, Emanuele, additional, Maggi, Fabrizio, additional, Vaia, Francesco, additional, Girardi, Enrico, additional, and Antinori, Andrea, additional

Published
2023
Full Text
View/download PDF

2. HCV cirrhotic patients treated with direct‐acting antivirals: Detection of tubular dysfunction and resolution after viral clearance

Author

Biliotti, Elisa, primary, Palazzo, Donatella, additional, Tinti, Francesca, additional, D'Alessandro, Maria Domenica, additional, Esvan, Rozenn, additional, Labriola, Raffaella, additional, Cappoli, Andrea, additional, Umbro, Ilaria, additional, Volpicelli, Lorenzo, additional, Bachetoni, Alessandra, additional, Villa, Erica, additional, Mitterhofer, Anna Paola, additional, Rucci, Paola, additional, and Taliani, Gloria, additional

Published
2020
Full Text
View/download PDF

6. Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort.

Author

Kondili LA, Zanetto A, Quaranta MG, Ferrigno L, Panetta V, Calvaruso V, Zignego AL, Brunetto MR, Raimondo G, Biliotti E, Ieluzzi D, Iannone A, Madonia S, Chemello L, Cavalletto L, Coppola C, Morisco F, Barbaro F, Licata A, Federico A, Cerini F, Persico M, Pompili M, Ciancio A, Piscaglia F, Chessa L, Giacometti A, Invernizzi P, Brancaccio G, Benedetti A, Baiocchi L, Gentile I, Coppola N, Nardone G, Craxì A, and Russo FP

Subjects
Humans, Antiviral Agents therapeutic use, Portal Vein, Liver Cirrhosis diagnosis, Liver Cirrhosis epidemiology, Liver Cirrhosis complications, Risk Assessment, Albumins therapeutic use, Bilirubin, Esophageal and Gastric Varices complications, Hepatitis C, Chronic complications, Hepatitis C, Chronic diagnosis, Hepatitis C, Chronic drug therapy, Venous Thrombosis diagnosis, Venous Thrombosis epidemiology, Venous Thrombosis etiology
Abstract

Background & Aims: Sustained virological response (SVR) by direct-acting antivirals (DAAs) may reverse the hypercoagulable state of HCV cirrhosis and the portal vein thrombosis (PVT) risk. We evaluated the incidence and predictive factors of de novo, non-tumoral PVT in patients with cirrhosis after HCV eradication., Methods: Patients with HCV-related cirrhosis, consecutively enrolled in the multi-center ongoing PITER cohort, who achieved the SVR using DAAs, were prospectively evaluated. Kaplan-Meier and competing risk regression analyses were performed., Results: During a median time of 38.3 months (IQR: 25.1-48.7 months) after the end of treatment (EOT), among 1609 SVR patients, 32 (2.0%) developed de novo PVT. A platelet count ≤120,000/μL, albumin levels ≤3.5 mg/dL, bilirubin >1.1 mg/dL, a previous liver decompensation, ALBI, Baveno, FIB-4, and RESIST scores were significantly different (p < 0.001), among patients who developed PVT versus those who did not. Considering death and liver transplantation as competing risk events, esophageal varices (subHR: 10.40; CI 95% 4.33-24.99) and pre-treatment ALBI grade ≥2 (subHR: 4.32; CI 95% 1.36-13.74) were independent predictors of PVT. After HCV eradication, a significant variation in PLT count, albumin, and bilirubin (p < 0.001) versus pre-treatment values was observed in patients who did not develop PVT, whereas no significant differences were observed in those who developed PVT (p > 0.05). After the EOT, esophageal varices and ALBI grade ≥2, remained associated with de novo PVT (subHR: 9.32; CI 95% 3.16-27.53 and subHR: 5.50; CI 95% 1.67-18.13, respectively)., Conclusions: In patients with HCV-related cirrhosis, a more advanced liver disease and significant portal hypertension are independently associated with the de novo PVT risk after SVR., (© 2023 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results